Neurocrine Biosciences | Koszty Sprzedaży I Administracji



Selling And Administration Expenses Zmiana Data
AbbVie USD 3.25B 40M 2025-06
Acadia Pharmaceuticals USD 123.66M 2.71M 2025-06
Agios Pharmaceuticals USD 45.87M 4.34M 2025-06
ALKERMES USD 153.87M 17.83M 2025-06
Alnylam Pharmaceuticals USD 323.31M 83.36M 2025-06
Amgen USD 1.69B 4M 2025-06
Biogen USD 583.8M 11.3M 2025-06
BioMarin Pharmaceutical USD 232.28M 26.16M 2025-06
Cytokinetics USD 65.72M 8.35M 2025-06
Dynavax Technologies USD 41.54M 64.79M 2025-06
Exelixis USD 134.86M 2.32M 2025-07
Gilead Sciences USD 1.36B 100M 2025-06
Halozyme Therapeutics USD 33M 9.36M 2025-06
Incyte USD 331.02M 5.33M 2025-06
Ionis Pharmaceuticals USD 90.6M 14.6M 2025-06
Neurocrine Biosciences USD 286.3M 9.8M 2025-06
Pfizer USD 3.42B 406M 2025-06
Prothena USD 16.85M 88K 2024-12
Regeneron Pharmaceuticals USD 634.2M 1.2M 2025-06
Repligen USD 71.23M 28K 2025-06
Sarepta Therapeutics USD 69.89M 63.74M 2025-06
Teva Pharmaceutical Industries USD 959M 40M 2025-06
Ultragenyx Pharmaceutical USD 86.65M 1.15M 2025-06
Vertex Pharmaceuticals USD 424.6M 28.2M 2025-06


Neurocrine Biosciences Koszty Sprzedaży I Administracji - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Aug 2025.